SGLT2
Phase 3Small molecule
SGLT2 is one of 33 small molecule programs targeting Hypertension. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
157 competitors in Hypertension
#DrugCompanyPhaseTrials
1Foundayo
Eli LillyPhase 3
Baxfendy
AstraZenecaPhase 3
Nitrostat
VViatris Specialty LLC
Phase 3
Alka-Seltzer
AAbbott
Phase 3
SGLT2
PProf. Dr. med. Ingo Eitel
Phase 3
HCP1803-3
Hanmi Pharmaceutical Company LimitedPhase 3
Avastin
RochePreclinical
Winrevair
Merck & Co.Preclinical
Alphagan
AbbViePreclinical
Deltavit
HHyundai Pharmaceutical Co., LTD.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiovascular1 trial
Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)
Unknown status·—··NCT03627039·20,000 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SGLT2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PProf. Dr. med. Ingo Eitel